Atara Biotherapeutics Book Value Per Share Growth & History (ATRA)
Atara Biotherapeutics's book value per share was -$5.26 for fiscal 2025.
View full Atara Biotherapeutics company overviewAtara Biotherapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$5.26 | $11.35 | — |
| 2024 | 2024-12-31 | -$16.60 | -$39.91 | — |
| 2023 | 2023-12-31 | $23.30 | -$9.70 | −29.39% |
| 2022 | 2022-12-31 | $33.00 | -$43.25 | −56.72% |
| 2021 | 2021-12-31 | $76.25 | -$62.38 | −45.00% |
| 2020 | 2020-12-31 | $138.64 | $10.67 | +8.33% |
| 2019 | 2019-12-31 | $127.97 | -$56.58 | −30.66% |
| 2018 | 2018-12-31 | $184.56 | $39.86 | +27.54% |
| 2017 | 2017-12-31 | $144.70 | -$74.55 | −34.00% |
| 2016 | 2016-12-31 | $219.24 | -$57.56 | −20.79% |
| 2015 | 2015-12-31 | $276.80 | $145.81 | +111.32% |
| 2014 | 2014-12-31 | $130.99 | $153.93 | — |
| 2013 | 2013-12-31 | -$22.94 | — | — |
Atara Biotherapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$3.92 | $1.10 | — |
| Q1 2026 | 2026-03-31 | -$4.38 | $4.91 | — |
| Q4 2025 | 2025-12-31 | -$5.26 | $11.35 | — |
| Q3 2025 | 2025-09-30 | -$5.08 | $10.69 | — |
| Q2 2025 | 2025-06-30 | -$5.02 | $17.59 | — |
| Q1 2025 | 2025-03-31 | -$9.30 | $11.13 | — |
| Q4 2024 | 2024-12-31 | -$16.60 | -$39.91 | — |
| Q3 2024 | 2024-09-30 | -$15.77 | -$3.30 | — |
| Q2 2024 | 2024-06-30 | -$22.61 | -$24.45 | — |
| Q1 2024 | 2024-03-31 | -$20.43 | -$37.25 | — |
| Q4 2023 | 2023-12-31 | $23.30 | -$9.70 | −29.39% |
| Q3 2023 | 2023-09-30 | -$12.47 | -$61.77 | — |
| Q2 2023 | 2023-06-30 | $1.84 | -$66.38 | −97.30% |
| Q1 2023 | 2023-03-31 | $16.82 | -$43.22 | −71.98% |
| Q4 2022 | 2022-12-31 | $33.00 | -$43.25 | −56.72% |
| Q3 2022 | 2022-09-30 | $49.30 | -$38.42 | −43.80% |
| Q2 2022 | 2022-06-30 | $68.22 | -$29.57 | −30.24% |
| Q1 2022 | 2022-03-31 | $60.04 | -$58.62 | −49.40% |
| Q4 2021 | 2021-12-31 | $76.25 | -$62.38 | −45.00% |
| Q3 2021 | 2021-09-30 | $87.72 | -$26.86 | −23.44% |
| Q2 2021 | 2021-06-30 | $97.79 | -$30.43 | −23.73% |
| Q1 2021 | 2021-03-31 | $118.66 | $11.42 | +10.65% |
| Q4 2020 | 2020-12-31 | $138.64 | $10.67 | +8.33% |
| Q3 2020 | 2020-09-30 | $114.59 | -$32.50 | −22.10% |
| Q2 2020 | 2020-06-30 | $128.22 | $4.36 | +3.52% |
| Q1 2020 | 2020-03-31 | $107.24 | -$46.05 | −30.04% |
| Q4 2019 | 2019-12-31 | $127.97 | -$56.58 | −30.66% |
| Q3 2019 | 2019-09-30 | $147.09 | -$73.67 | −33.37% |
| Q2 2019 | 2019-06-30 | $123.86 | -$125.68 | −50.36% |
| Q1 2019 | 2019-03-31 | $153.29 | -$96.86 | −38.72% |
| Q4 2018 | 2018-12-31 | $184.56 | $39.86 | +27.54% |
| Q3 2018 | 2018-09-30 | $220.75 | $52.47 | +31.18% |
| Q2 2018 | 2018-06-30 | $249.54 | $64.66 | +34.97% |
| Q1 2018 | 2018-03-31 | $250.14 | $49.92 | +24.93% |
| Q4 2017 | 2017-12-31 | $144.70 | -$74.55 | −34.00% |
| Q3 2017 | 2017-09-30 | $168.29 | -$65.92 | −28.15% |
| Q2 2017 | 2017-06-30 | $184.88 | -$67.90 | −26.86% |
| Q1 2017 | 2017-03-31 | $200.23 | -$65.53 | −24.66% |
| Q4 2016 | 2016-12-31 | $219.24 | -$57.56 | −20.79% |
| Q3 2016 | 2016-09-30 | $234.21 | -$60.35 | −20.49% |
| Q2 2016 | 2016-06-30 | $252.77 | $98.28 | +63.61% |
| Q1 2016 | 2016-03-31 | $265.75 | $92.10 | +53.04% |
| Q4 2015 | 2015-12-31 | $276.80 | $145.81 | +111.32% |
| Q3 2015 | 2015-09-30 | $294.56 | $675.91 | — |
| Q2 2015 | 2015-06-30 | $154.50 | — | — |
| Q1 2015 | 2015-03-31 | $173.65 | — | — |
| Q4 2014 | 2014-12-31 | $130.99 | $153.93 | — |
| Q3 2014 | 2014-09-30 | -$381.35 | — | — |
| Q4 2013 | 2013-12-31 | -$22.94 | — | — |
Atara Biotherapeutics book value per share trends
Over the last five fiscal years, Atara Biotherapeutics's book value per share decreased from $138.64 to -$5.26, a change of -$143.89. The latest reported quarter, Q2 2026, shows -$3.92.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Atara Biotherapeutics source filings ↗